Press releases

Copenhagen, Denmark, 2 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that SEB reiterates a fair value for Curasight's shares of DKK 54 per share, which implies an upside of 370% from the TO2 warrant strike price of DKK 11.50

The 3[rd] of December 2024 is the last day of trading in warrants of series TO2, which were issued in connection with Curasight A/S ("Curasight" or the "Company") preferential rights issue and directed issue of units in September 2024. The exercise period runs until the 5[th] of December 2024.

· Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming pivotal therapy trials
· The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer

Copenhagen, Denmark, November 22 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announced today that it has entered into a clinical supply agreement with Curium – a global leader in radiopharmaceuticals – for the supply of non-carrier-added Lutetium-177 for Curasight’s uTREAT®.

Copenhagen, Denmark, 21 November 2024 - Today is the first day for the exercise of Curasight A/S’ ("Curasight" or "the Company" - TICKER: CURAS) warrants of series TO2 (“TO2”), which were issued in connection with the Company's preferential rights issue and directed issue of units in September 2024. The exercise period will run until December 5, 2024. Holders of TO2 are entitled to subscribe for one (1) new share in Curasight for each TO2 at an exercise price of DKK 11.50 per share. If all warrants of series TO2 are exercised, Curasight can receive a maximum of approximately DKK 42.4 million before the deduction of issue costs. An information document is available on the respective websites of Curasight (www.curasight.com) and Sedermera Corporate Finance AB (www.sedermera.se).

Business Highlights during and after the third quarter of 2024

· Curasight designates brain cancer as initial indication for uTREAT
· Clinical Phase II trial of uPAR-PET in brain cancer patients
· Strong demand for rights issue resulted in heavy oversubscription
· Continued business development activities with industry players

Copenhagen, Denmark, 21 November 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the third quarter, and the first nine months, 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby announces that the exercise price for the warrants of series TO2 (”TO2”), which were issued in connection with the directed issue and rights issue of units the Company executed earlier during 2024, has been set. The exercise price for TO2 has been set to DKK 11.50 per share and the exercise period commences on 21 November 2024.

Copenhagen, Denmark, 14 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kjær will present the company’s latest progress and strategy at HC Andersen Capital, BioStock Life Science Summit 2024 and Økonomisk Ugebrev Life Science Investor Conference

· New patent application related to uTREAT will extend patent protection until 2043
· Application adds several new alpha- and beta-emitters to protection under existing issued patents
· Application strengthens patent family for Curasight’s uPAR-targetting technology, aimed at improving cancer diagnosis (uTRACE) and treatment (uTREAT)

Copenhagen, Denmark, 13 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today the publication of its international patent application for uTREAT®. The patent application is in addition to already granted patents covering the company’s peptide-based uPAR-targeting technology and if granted will extend patent protection to 2043.

· Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT[®]
· Addresses a clear unmet medical need
· Clinical development plan established
· Clinical trial application (CTA) submission anticipated early Q1 2025
· First patient dosed with uTREAT late Q2 2025

Copenhagen, Denmark, 11 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that it has chosen brain cancer (high-grade glioma (HGG)) as the first indication for uTREAT[®] as a potential cancer therapeutic. The company aims to dose the first patient with uTREAT[®] end of Q2 2025.

Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO Andreas Kjær have been invited to present the company’s latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen 11 November 2024